Is surgical castration (bilateral orchiectomy) ever used in the treatment of localized or metastatic prostate cancer?

Is Surgical Castration (Bilateral Orchiectomy) Still Used in Prostate Cancer?

Yes, bilateral orchiectomy (surgical castration) remains a valid and guideline-endorsed option for both localized high-risk and metastatic prostate cancer, though it is significantly underutilized in contemporary practice.

Guideline-Based Recommendations

Equivalence to Medical Castration

LHRH agonist/antagonist (medical castration) and bilateral orchiectomy (surgical castration) are equally effective for androgen deprivation therapy 1, 2, 3. The NCCN Guidelines explicitly state this equivalence across multiple versions spanning 2010-2021, establishing surgical castration as a standard first-line option 1, 4, 2.

The ESMO guidelines similarly confirm that "androgen suppression using bilateral orchiectomy or an LHRH agonist/antagonist should be first-line treatment" for metastatic disease 5. ASCO guidelines from 2004 and 2021 reinforce that both methods achieve equivalent testosterone suppression and clinical outcomes 6, 7.

Clinical Settings Where Orchiectomy Is Appropriate

For Metastatic Disease:

• Bilateral orchiectomy is a category 1 recommendation as initial ADT for metastatic prostate cancer 1, 3
• It provides immediate, permanent castration without concerns about medication adherence
• Particularly valuable for patients with symptomatic metastases requiring rapid testosterone suppression

For High-Risk Localized Disease:

• When ADT is combined with radiation therapy for high-risk or locally advanced disease, surgical castration can substitute for medical castration 2, 5
• The choice between surgical and medical approaches should be based on patient preference, cost considerations, and practical factors

Real-World Utilization Patterns

Despite guideline endorsement, surgical castration use has declined dramatically from 8.5% in 2004 to 3.5% in 2016 in the United States 8. Currently, only 5.4% of men with metastatic prostate cancer undergo bilateral orchiectomy 8. A 2022 survey found that only 7.5% of urologists and medical oncologists routinely offer surgical castration to patients 9.

Factors Associated with Surgical Castration Use

Patients more likely to receive orchiectomy include those with:

• Medicaid or no insurance (OR 1.68-2.12 compared to Medicare) 8
• Lower regional median income (<$38,000) 8
• Medication adherence issues (18.4% of orchiectomy patients had prior ADT compliance problems) 10
• Treatment at public academic hospitals versus private facilities 10

Clinical Advantages of Surgical Castration

Biochemical Efficacy

All patients achieve castrate testosterone levels (<50 ng/dL) after orchiectomy, with median levels of 10 ng/dL 10. Research suggests bilateral orchiectomy may achieve lower castrate testosterone levels than LHRH antagonists, potentially associated with better disease control 11.

Practical Benefits

• One-time procedure eliminating need for ongoing injections and follow-up
• Lower long-term cost compared to continuous medical therapy
• Guaranteed compliance - no risk of missed doses or treatment interruptions
• Rapid testosterone suppression without flare phenomenon (unlike LHRH agonists)
• Low complication rate of 3.0% 10

Quality of Life Considerations

Contrary to assumptions about psychological impact, bilateral orchiectomy was associated with better health-related quality of life, global health status, and functional status compared to LHRH antagonist therapy in comparative studies 11, 12. No significant psychological problems related to organ loss were documented 12.

Survival Outcomes

Surgical versus medical castration shows equivalent overall survival (HR 1.02,95% CI 0.95-1.09, p=0.6) after median follow-up of 30 months 8. In metastatic disease, median overall survival was 36 months with orchiectomy, with median time to tumor progression of 29 months 12.

Surgical Techniques

Two approaches are available:

• Simple orchiectomy (80.2% of cases) - complete removal of testes
• Epididymal-sparing orchiectomy (19.8% of cases) - preserves epididymis for cosmetic purposes

Both techniques achieve equivalent castrate testosterone levels (p=0.90) with no difference in efficacy 10.

Barriers to Use

Physician-Related Factors

Medical oncologists prefer surgical castration less than urologists (p=0.003) due to concerns about:

• Invasive nature of the procedure
• Perceived morbidity/mortality risk
• Hospitalization costs
• Body image concerns 9

Systemic Issues

• Pharmaceutical industry influence on treatment selection 9
• Physician knowledge gaps about orchiectomy benefits 9
• Biased presentation of treatment options to patients 9
• Perception that surgery is "anachronistic" despite evidence supporting its use 12

Clinical Algorithm for Selecting Castration Method

Consider bilateral orchiectomy preferentially when:

1. Patient has medication adherence concerns or history of non-compliance
2. Limited healthcare access or financial constraints make ongoing medical therapy challenging
3. Patient preference after balanced counseling about both options
4. Symptomatic metastatic disease requiring immediate, guaranteed testosterone suppression
5. Patient desires one-time definitive treatment

Medical castration may be preferred when:

1. Patient strongly objects to surgical procedure
2. Intermittent ADT is planned (requires reversibility)
3. Patient is enrolled in clinical trials requiring specific ADT protocols
4. Very short life expectancy where surgery risk outweighs benefit

Common Pitfalls to Avoid

• Failing to offer orchiectomy as an option - This violates guideline recommendations and may reflect physician bias rather than evidence-based practice
• Assuming psychological harm - Evidence shows no significant psychological problems and potentially better QOL with surgery 11, 12
• Overestimating surgical risk - Complication rates are low (3%) and comparable to medical therapy side effects 10
• Ignoring cost-effectiveness - Surgical castration has significant economic advantages for long-term treatment
• Not considering compliance issues - Patients with adherence problems benefit substantially from permanent castration

The evidence clearly supports bilateral orchiectomy as an underutilized, guideline-endorsed, and clinically effective option that deserves reconsideration in contemporary prostate cancer management 1, 2, 5, 3, 11.